INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Phase 1/2
Active, not recruiting
NCT04455841
| Condition | Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Incyte Corporation |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 84 participants |
|---|
| Interventions | INCB000928, ruxolitinib |
|---|
| Start date | Mar 19, 2021 |
|---|
| Completion date | Apr 1, 2025 |
|---|
| Results posted | May 12, 2026 |
|---|
Summary
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)
up to approximately 4 years · Participants
| Zilurgisertib Monotherapy 50 mg QD | 4 Participants |
|---|
| Zilurgisertib Monotherapy 100 mg QD | 4 Participants |
|---|
| Zilurgisertib Monotherapy 200 mg QD | 6 Participants |
|---|
| Zilurgisertib Monotherapy 400 mg QD | 11 Participants |
|---|
| Zilurgisertib Monotherapy 600 mg QD | 4 Participants |
|---|
| Zilurgisertib Monotherapy 300 mg BID | 3 Participants |
|---|
Number of Participants With Any ≥Grade 3 TEAE and Any Treatment-emergent SAE
up to approximately 4 years · Participants
| Zilurgisertib Monotherapy 50 mg QD | 1 Participants |
|---|
| Zilurgisertib Monotherapy 100 mg QD | 0 Participants |
|---|
| Zilurgisertib Monotherapy 200 mg QD | 5 Participants |
|---|
| Zilurgisertib Monotherapy 400 mg QD | 3 Participants |
|---|
| Zilurgisertib Monotherapy 600 mg QD | 2 Participants |
|---|
| Zilurgisertib Monotherapy 300 mg BID | 2 Participants |
|---|
Number of Participants With Dose-limiting Toxicities (DLTs)
from Cycle 1 Day 1 to Cycle 1 Day 28 · Participants
| Zilurgisertib Monotherapy 50 mg QD | 0 Participants |
|---|
| Zilurgisertib Monotherapy 100 mg QD | 0 Participants |
|---|
| Zilurgisertib Monotherapy 200 mg QD | 0 Participants |
|---|
| Zilurgisertib Monotherapy 400 mg QD | 0 Participants |
|---|
| Zilurgisertib Monotherapy 600 mg QD | 0 Participants |
|---|
| Zilurgisertib Monotherapy 300 mg BID | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.